Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cellular Ligand-Receptor Perturbations Unravel MEIS2 as a Key Factor for the Aggressive Progression and Prognosis in Stage II/III Colorectal Cancer.

Journal of proteome research - 2 Feb 2024

Xu Hui, Chen Shuang, Li Jing, Weng Siyuan, Ren Yuqing, Zhang Yuyuan, Wang Libo, Liu Long, Guo Chunguang, Xing Zhe, Luo Peng, Cheng Quan, Han Xinwei, Liu Zaoqu

Abstract excerpt

Approximately 10-15% of stage II and 25-30% of stage III colorectal cancer (CRC) patients experience recurrence within 5 years after surgery, and existing taxonomies are insufficient to meet the needs of clinical precision treatment. Thus, robust biomarkers and precise management were urgently required to stratify stage II and III CRC and identify potential patients who will benefit from postoperative adjuvant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homeodomain Proteins

Share to Ligands

Share to Neoplasm Staging

Share to Prognosis

Share to Signal Transduction

Share to Transcription Factors

Source

Identifiers

PMID: 38153233
DOI: 10.1021/acs.jproteome.3c00626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cellular Ligand-Receptor Perturbations Unravel MEIS2 as a Key Factor for the Aggressive Progression and Prognosis in Stage II/III Colorectal Cancer.PMID 38153233Read ↗

A novel prognostic signature of immune‐related genes for patients with colorectal cancerSemantic proximity Read ↗

The consensus molecular subtypes of colorectal cancer.Semantic proximity Read ↗

Construction of immune-related lncRNA signature to predict aggressiveness, immune landscape, and drug resistance of colorectal cancerSemantic proximity Read ↗

Integrating the Secretome and Interactome to Identify Novel Biomarkers and Therapeutic Targets in Colorectal CancerSemantic proximity Read ↗

Immune Landscape Refines the Classification of Colorectal Cancer With Heterogeneous Prognosis, Tumor Microenvironment and Distinct Sensitivity to Frontline TherapiesSemantic proximity Read ↗

A Comprehensive Multi-Omics Analysis Identifies a Robust Scoring System for Cancer-Associated Fibroblasts and Intervention Targets in Colorectal CancerSemantic proximity Read ↗

Comprehensive characterization of tumor microenvironment in colorectal cancer via histopathology-molecular analysisSemantic proximity Read ↗

Integrative network modeling of colorectal cancer reveals diagnostic signatures and therapeutic targetsSemantic proximity Read ↗

Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities.Semantic proximity Read ↗

Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapySemantic proximity Read ↗

Multi-omics cluster defines the subtypes of CRC with distinct prognosis and tumor microenvironmentSemantic proximity Read ↗

Revisiting the immune microenvironment of human colorectal cancer in the era of single-cell and spatial omicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.